Skip to main content
Clinical Trials/IRCT20160530028173N5
IRCT20160530028173N5
Recruiting
Phase 3

Comparison of the effects and side effects of the three drugs risperidone, quetiapine and olanzapine in the treatment of psychosis symptoms due to Shisheh

Tabriz University of Medical Sciences0 sites45 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Tabriz University of Medical Sciences
Enrollment
45
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Having criteria for glass\-induced psychosis disorder based on DSM\-5 (through clinical interview by psychiatrist).
  • Treated with one of the antipsychotics risperidone, quetiapine and olanzapine
  • No other psychiatric disorders
  • Willingness of an individual or family (conscious consent) to participate in the study
  • Minimum age 18
  • If you have a history of drug treatment for the above disorder, at least three weeks have passed since you stopped taking the drug

Exclusion Criteria

  • History of mental disorders
  • History of epilepsy
  • History of brain trauma
  • Taking drugs other than target group treatment drugs
  • Unwillingness of the patient or the family to continue cooperating in the study for any reason
  • Incomplete questionnaires
  • If a sample has other psychiatric disorders, including personality disorders, it will be excluded from the plan and will continue its routine treatment.
  • Incidence of drug complications based on the AIMS scale

Outcomes

Primary Outcomes

Not specified

Similar Trials